ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD
Sixty percent of dupilumab-treated patients with AD treated with 400mg of eblasakimab weekly achieved EASI-90 after 16 weeks.
Sixty percent of dupilumab-treated patients with AD treated with 400mg of eblasakimab weekly achieved EASI-90 after 16 weeks.
Leading dermatologists explore key benchmarks, emerging trends, personalized medicine approaches, and more in atopic dermatitis.
We are pleased to invite you to the 2024 Psychiatry Update – a three-day meeting with renowned faculty and informative presentations on bipolar disorder, MDD,…
Renata Block, MMS, PA-C, shares her favorite topics from the aesthetic conference held last month.
Cre ate a non-member account if you are applying for membership or need to interact with AAD systems. Non-member accounts do not have access to…
Patients who responded to imsidolimab in GEMINI-1 and who moved into GEMINI-2 maintained clear or almost clear skin.
A prebiotic cleanser and moisturizer regimen not only significantly alleviated the severity of atopic dermatitis and xerosis, but also uncovered crucial differences in symptom experiences.
Boehringer Ingelheim anounced that it has received FDA approval for a high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm). According to a press release from the company,…
Topical Bacitracin, Neosporin, and Vaseline were applied to mice over a 6-week period.
In this era of rising inflation and decreasing reimbursement, dermatologists must seek creative ways to provide excellent care while ensuring that patients maintain access to…
The awarded grant will span a total of 3 years.